Key figures (Sep 2011 - Oct 2017)
Some former students' testimonials
It is one of the very demanding and stringent courses I have done and that exemplifies the emphasis that the organization places on quality thereby ensuring that they develop core competency to the highest in professionals taking the course.
I enjoyed working on Eu2P! Despite being online it is well thought-through, forces you to learn and with this guarantees success (because learning is what you want, right?). The course was highly relevant for my daily work and I can only recommend this one (Statistics) to others.
The great thing of Eu2P is to meet people all around the world and discuss several topics related to Pharmacovigilance (signal detection, risk communication of medicines, regulations not only of the pharmaceutical drugs but also vaccines, devices in Europe, USA and Japan).
Eu2P is an amazing, well-designed and a “can’t miss” opportunity for those who work or would like to work in drug regulation, Pharma industry, academia, public health and other related fields
The practical experience and case study approach makes it a real-world situation adaptable to my current professional life. This is most appreciated. [...] I have recommended and will definitely continue recommending Eu2P!
I couldn’t think of a better programme than Eu2P when it came to excelling in career with broader horizon and widening my knowledge of drug affairs.
Organisations trusting us for staff competency development
- Real-life practices inputs from insiders such as the regulatory and industry members of the Eu2P consortium and from international guest experts invited to share experience and interact with students
- Course compliance with the core competencies and knowledge requirements such as WHO-ISoP requirements for pharmacovigilance and ISPE requirements for pharmacoepidemiology and with the imi-train competency profiles in Drug Safety Sciences
- Inclusion of last research and methodologies advances in collaboration with the IMI PROTECT stakeholders
- The full online courses approach to ease professional study-time management has been awarded a trophy for higher education innovation (Educatec-Educatice 2012)
- Modular and time flexible courses comply with lifelong learning and continuing professional development as described by the LifeTrain initiative
- Academic standards and quality of the programme are ensured by the Eu2P Executive Board including academic representatives of the 6 Eu2P degree awarding universities
- Compliance with main quality items of ENQA's report on "Standards and Guidelines for Quality Assurance in the European Higher Education Area"
- Cross quality review of assessments between Eu2P academic partners
- Independent external examination of programme assessments and equity
Recommendations & collaborations
Eu2P training programme is recommended by the ENCePP
as important in building future capacity in the European Union to undertake high quality, scientifically independent research.
IMI PROTECT project and Eu2P foster collaboration in postgraduate training and exchange of trainees between pharmacovigilance and pharmacoepidemiology centres. PROTECT also provides pharmacoepidemiological research findings and new methodology inputs for Eu2P teaching materials and programmes.
Eu2P training programme has been awarded a PharmaTrain Centre Recognition following a quality assessment of its Master Education and Training programme by The PharmaTrain Federation.
IMI EMTRAIN's On-course®, the European portal of biomedical postgraduate education and training resources is indexing Eu2P courses and providing a Eu2P course filter in its Advanced Search feature.
IMI SafeSciMET is collaborating with Eu2P to adapt course modules into blended learning format on the Eu2P eLearning platform under the collaborative framework of the imi-train project.
IMI European platform for education and training in the medical, biomedical and pharmaceutical sciences, imi-train, is promoting Eu2P academic postgraduate programmes as well as CPD training in pharmacovigilance and pharmacoepidemiology.
Publications & media highlights
- What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects.
R. van Eekeren, L. Rolfes, A.S. Koster, L. Magro, G. Parthasarathi, H. Al Ramimmy, T. Schutte, D. Tanaka, E. van Puijenbroek, L. Härmark
Drug Saf (2018). https://doi.org/10.1007/s40264-018-0681-z.
- 'All this wouldn’t have been possible without IMI' - an interview with Eu2P project coordinators.
IMI JU in Success stories from projects, 01 February 2018.
- Carrying the torch for medical innovation.
IMI JU in IMI Results and Impact, 06 Octobre 2017.
- Risk Communication in a Pharmacovigilance Environment.
Clinical Therapeutics. 39, no. 4 (April 2017): 672–74.
- An Introduction to Pharmacovigilance, 2nd Edition.
P. Waller, and M. Harrison-Woolrych
Wiley-Blackwell, April 2017.
- Practical Implementation in Six Member States.
M. Kaeding, J. Schmälter, C. Klika. in Pharmacovigilance in the European Union : Practical Implementation across Member States, edited by Wiesbaden: Springer, February 2017.
- البرنامج الأوروبي في اليقظة الدوائية: درجة الماجستير في اليقظة الدوائية عن بعد [European programme in pharmacovigilance: distant pharmacovigilance Master programme]
هاجر علي [Hager Ali]
Egypt Scholars blog May, 2017
- From Face-to-Face training to blended learning in the postgraduate program SafeSciMET - a case study.
J.C. Vos, S. Dragovic, M. Jochimsen, J. Dirach, H. Foth, J. Wiese, O.J. Bjerrum
Eur. J. Pharm. Sci., 01 January 2017.
- Opportunities and Challenges for Drug Development: Public–Private Partnerships, Adaptive Designs and Big Data.
O. Yildirim, M. Gottwald, P. Schüler and M.C. Michel
Front. Pharmacol., 06 December 2016.
- Job and Career Opportunities in the Pharmaceutical Sector.
J.R. Thomas, C. van Schravendijk, L. Smit and L. Saso.
In Special Topics in Drug Discovery, edited by T. Chen and S.C. Chai, November 2016.
- Elaboration et évaluation d’un site d’e-learning pour l’apprentissage de la recherche en médecine générale.
N. De Chanaud.
Thèse de Médecine Générale, 27 septembre 2016.
- How can an adaptive training programme support change in organisational strategy?
Intrinsic Activity, 2016; 4 (Suppl. 1): A4.1
- Essential learnings: How do I begin...?
benefit-risk assessment, the blog around structured decision making in medicine, June, 2016
- Shaping Europe's Vision for Personalised Medicine.
The PerMed SRIA (Strategic Research and Innovation Agenda), Jul. 2015.
- Structured Benefit–risk Assessment: A Review of Key Publications and Initiatives on Frameworks and Methodologies.
S. Mt-Isa, M. Ouwens, V. Robert, M. Gebel, A. Schacht, and I. Hirsch.
Pharmaceutical Statistics, May 2015.
- European Initiatives for Better Training in Medicines Development.
Journal of Medicines Development Sciences 1, no. 1 (May 2015).
- Guide de Conception de Formation Ouverte et à Distance (FOAD) Dans Le Monde de La Santé.
Haute Autorité de santé, Apr. 2015.
- The Innovative Medicines Initiative: an engine for regulatory science.
M. Goldman, N. Seigneuret, H.G. Eichler
Nat Rev Drug Discov. 2015 Jan;14(1):1-2.
- Chapter 6 - How Can the Innovative Medicines Initiative Help to Make Medicines Development More Efficient?
In Re-Engineering Clinical Trials, 55–63. Elsevier - Academic Press, Jan. 2015.
- Teaching Pharmacovigilance: The WHO-ISoP Core Elements of a Comprehensive Modular Curriculum.
J. Beckmann, U. Hagemann, P. Bahri, A. Bate, I.W. Boyd, G.J. Dal Pan, B.D. Edwards, et al.
Drug Safety, Aug. 2014, 1–17.
- Practical Experience in Teaching Pharmacovigilance.
S. Evans, and I. Douglas
In Mann's Pharmacovigilance, 805–6. John Wiley & Sons, Ltd, Apr. 2014.
- Eu2P: The First European Online Public–Private Joint Training Program in Pharmacovigilance and Pharmacoepidemiology.
K. Palin, C. Bataille, S. Liège, R. Schimmer, and A. Fourrier-Réglat
In Mann's Pharmacovigilance, 785–92. John Wiley & Sons, Ltd, Apr. 2014.
- Bordeaux : L'Université Se Met Au Numérique.
France 3 Aquitaine. Feb. 2014.
- Towards a Single VOICE for European Clinical Pharmacology: Proposals for Future Developments.
J.K. Aronson and G. Velo.
European Journal of Clinical Pharmacology 69, no. 11 (Nov. 2013): 1981–84.
- La Formation à Distance 'Made in Aquitaine' Qui Intéresse Harvard.
Journal l'Aquitaine, journal d'information du Conseil Régional d'Aquitaine, Sep. 2013.
- Prescrire juste, plutôt que juste prescrire.
M. Molimard, M.-C. Perault-Pochat, C. Funck-Brentano, M. Bardou, R. Bordet, and J.-L. Montastruc.
Le Monde.fr, Apr. 2013.
- Regulatory Science: Researchers in the Pipeline.
Nature 496, no. 7445 (Apr. 2013): 387–89.
- Opening Industry-Academic Partnerships.
Science, Apr. 2013.
- Enseignement : Bordeaux Segalen Tient La Distance.
Sud-Ouest Feb. 2013.
- Continuing Medical Education and Professional Development in the European Union.
H. Silva, F.R. Bühler, B. Maillet, H. Maisonneuve, L.A. Miller, A. Negri, and P.D. Stonier.
Pharmaceutical Medicine 26, no. 4 (Dec. 2012): 223–33.
- Better Comms in Meds.
K. Palin, C. Bataille, S. Liège, E. Swain, A. Fourrier-Réglat, and R. Schimmer.
Public Service Review: Health and Social Care, no. 34 (Dec. 2012): 71.
- TV report on Eu2P programme
Emission Modes d'Emplois.
TV7 Bordeaux, Nov. 2012.
- Pharmacovigilance Medical Writing: A Good Practice Guide
Wiley-Blackwell, July 2012
- European Initiative towards Quality Standards in Education and Training for Discovery, Development and Use of Medicines.
H. Klech, C. Brooksbank, S. Price, P. Verpillat, F.R. Bühler, D. Dubois, N. Haider, et al.
European Journal of Pharmaceutical Sciences 45, no. 5 (Apr. 2012): 515–20.
- The Innovative Medicines Initiative: A European Response to the Innovation Challenge.
Clinical Pharmacology & Therapeutics 91, no. 3 (Mar. 2012): 418–25.
- Cobert's Manual of Drug Safety and Pharmacovigilance.
Jones & Bartlett Learning 2011.
Overall, it was a very enriching experience completing the certificate program on benefit-risk assessment in drug development, offered by Eu2P. It is one of the very demanding and stringent courses I have done and that exemplifies the emphasis that the organization places on quality thereby ensuring that they develop core competency to the highest in professionals taking the course. I am sure that if another opportunity comes through my organization, I will definitely consider enrolling in other professional development courses as well, in addition to sharing my positive experiences with my colleagues and professional acquaintances.
I enjoyed working on Eu2P! Despite being online it is well thought-through, forces you to learn and with this guarantees success (because learning is what you want, right?). The course was highly relevant for my daily work and I can only recommend this one (Statistics) to others. Study materials and examples were indeed helpful in this topic. Teachers and contacts were easy to reach, responded immediately and were dedicated. So interaction worked perfectly. Also indeed inspiring to do this EU-wide with students coming from different EU countries. Not the only one but one eye-opening example why collaboration within the EU is great!
Eu2P was for me an unforgettable experience!!! I will recommend to all the people who want to have a good knowledge in Pharmacovigilance and pharmacoepidemiology. The Master programme gave me all the tools I needed for my professional life. The great thing of Eu2P is to meet people all around the world and discuss several topics related to Pharmacovigilance (signal detection, risk communication of medicines, regulations not only of the pharmaceutical drugs but also vaccines, devices in Europe, USA and Japan). Eu2P give you the chance so don’t miss it!
Eu2P is an amazing, well-designed and a “can’t miss” opportunity for those who work or would like to work in drug regulation, Pharma industry, academia, public health and other related fields. By the joining the Eu2P, I have solved lots of my doubts/challenges that I was encountering on my daily work. The e-learning platform is a class of its own; with intensive interaction and live sessions. After all, I have enjoyed the sense of the academic partnerships of the six universities with critical view from regulators, public health managers, insurers, patient representatives and so on. Eu2P is a proof for me that online PG programs can be achieved in an easier and comfortable way without compromising the quality of education and interaction. Now, confidently I am able to identify, evaluate and communicate several safety signals and assess benefits and risks of medicines. Besides, I am now involved as lead investigator in large observational cohort studies. Viva Eu2P! I am proud to be your product.
My experience at Eu2P was awesome! An absolutely very rich content with every sector experience, from the academia to industry to regulatory to healthcare providers to reimbursement to patient representative organizations to the consumer. Every perspective to a case is explored. The practical experience and case study approach makes it a real-world situation adaptable to my current professional life. This is most appreciated. The team at the Eu2P Central office are great minds and always available to assist where necessary making the programme doable with its tough content and demands. I have recommended and will definitely continue recommending Eu2P!
I couldn’t think of a better programme than Eu2P when it came to excelling in career with broader horizon and widening my knowledge of drug affairs. I envisioned the whole system with a totally new perspective and look forward to improving one in my homeland as well. The course is well designed, covering all necessary fields and timely response from most (if not all) of the mentors. Eu2P management is very cooperative and addresses its students’ issues amicably. I found some best mentors-for-life undoubtedly (especially Pr. Albert Figueras) and would like to accredit them for polishing one of my most desirable skills: Scientific Research!!